Prasugrel Oral Tablet — Competitive Intelligence Brief

Prasugrel Oral Tablet (Prasugrel Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist (thienopyridine). Area: Cardiovascular.

marketed P2Y12 receptor antagonist (thienopyridine) P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Prasugrel Oral Tablet (Prasugrel Oral Tablet) — Elliot Israel, MD. Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation and thrombosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prasugrel Oral Tablet TARGET	Prasugrel Oral Tablet	Elliot Israel, MD	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Clopidogrel 75	Clopidogrel 75	US Department of Veterans Affairs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Aspirin and thienopyridine	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
Aspirin + Clopidogrel + Rivaroxaban	Aspirin + Clopidogrel + Rivaroxaban	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa
Aspirin or thienopyridine	Aspirin or thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Antiplatelet agents	COX-1 (aspirin); P2Y12 receptor (thienopyridines)
Double antiplatelet therapy	Double antiplatelet therapy	University Hospital, Bordeaux	marketed	Antiplatelet combination therapy	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist (thienopyridine) class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Azienda Policlinico Umberto I · 1 drug in this class
3. Deutsches Herzzentrum Muenchen · 1 drug in this class
4. Elliot Israel, MD · 1 drug in this class
5. Research Maatschap Cardiologen Rotterdam Zuid · 1 drug in this class
6. Sanofi · 1 drug in this class